Get the Stockscreener App
1.31
9.17%
0.11
After Hours:
1.33
0.02
+1.53%
Outlook Therapeutics Inc stock is traded at $1.31, with a volume of 3.18M.
It is up +9.17% in the last 24 hours and up +25.96% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.20
Open:
$1.22
24h Volume:
3.18M
Relative Volume:
0.88
Market Cap:
$58.19M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.3275
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+20.18%
1M Performance:
+25.96%
6M Performance:
-5.07%
1Y Performance:
-74.56%
1-Day Range:
$1.22
$1.41
1-Week Range:
$1.08
$1.41
52-Week Range:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.31 | 53.30M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Can Outlook Therapeutics Inc. stock continue upward trendJuly 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Full technical analysis of Outlook Therapeutics Inc. stockJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
What earnings revisions data tells us about Outlook Therapeutics Inc. - newser.com
Real time pattern detection on Outlook Therapeutics Inc. stockBull Run & Verified Stock Trade Ideas - newser.com
Is Outlook Therapeutics Inc. (41ON) stock good for long term investingEarnings Summary Report & AI Driven Stock Movement Reports - newser.com
Is Outlook Therapeutics Inc a good long term investmentStock Buyback Announcements & Exceptional Trading Strategies - earlytimes.in
How sentiment analysis helps forecast Outlook Therapeutics Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
What does recent volatility data suggest for Outlook Therapeutics Inc.July 2025 Market Mood & Daily Oversold Stock Bounce Ideas - newser.com
Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Weiss Ratings Reaffirms "Sell (E+)" Rating for Oncobiologics (NASDAQ:OTLK) - MarketBeat
How Outlook Therapeutics Inc. (41ON) stock expands through international marketsWeekly Investment Recap & Capital Efficient Trading Techniques - newser.com
Can Outlook Therapeutics Inc. rally from current levels2025 Sector Review & Stock Portfolio Risk Control - newser.com
How Outlook Therapeutics Inc. stock performs in interest rate cyclesQuarterly Profit Review & Weekly High Potential Stock Alerts - newser.com
What is the fair value of Outlook Therapeutics Inc. stock now2025 Volatility Report & Long-Term Growth Stock Strategies - newser.com
Market reaction to Outlook Therapeutics Inc.’s recent newsShare Buyback & Safe Entry Point Alerts - newser.com
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
How to recover losses in Outlook Therapeutics Inc. stockJuly 2025 Selloffs & Consistent Income Trade Ideas - newser.com
Sentiment analysis tools applied to Outlook Therapeutics Inc.July 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
How Outlook Therapeutics Inc. (41ON) stock moves in volatile trading sessionsJuly 2025 Sentiment & Verified Momentum Watchlists - newser.com
Applying sector rotation models to Outlook Therapeutics Inc.Portfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Why Outlook Therapeutics Inc. (41ON) stock is favored by hedge fundsPortfolio Return Report & Low Risk High Win Rate Picks - newser.com
Is Outlook Therapeutics Inc. (41ON) stock attractive for growth fundsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Outlook To Resubmit Ophthalmic Bevacizumab To The FDA By Year End - insights.citeline.com
OTLK Receives Neutral Rating from HC Wainwright & Co. | OTLK Sto - GuruFocus
H.C. Wainwright maintains Neutral rating on Outlook Therapeutics stock - Investing.com India
H.C. Wainwright maintains Neutral rating on Outlook Therapeutics stock By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Reiterates Outlook Therapeutics (OTLK) Neutral Recommendation - Nasdaq
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):